使用多巴胺转运体PET示踪剂[18F]FECNT-d4评估多巴胺能神经元损伤
研究在单侧6-OHDA帕金森病模型大鼠和死后脑切片中评估氘代多巴胺转运体PET示踪剂[18F]FECNT-d4识别多巴胺能神经元变性的能力。PET显示损毁侧纹状体摄取随损伤程度加重而下降,并与行为学、免疫染色及单胺浓度相关;帕金森病患者死后纹状体切片摄取较健康者约低40%。
要点
- 轻度、中度、重度损毁组损毁侧与对侧纹状体SUV比值较假手术组分别下降13%、23%、63%。
- 帕金森病患者死后纹状体切片[18F]FECNT-d4摄取较健康者约低40%。
- 由大鼠生物分布估算的人体有效剂量当量为5.06 E-03 mSv/MBq,低于FDA辐射暴露限值。
核心结论
- [18F]FECNT-d4能准确评估6-OHDA诱导帕金森病大鼠模型的多巴胺能神经元变性水平,并有效区分帕金森病患者与健康个体。
- 作者认为该高灵敏度且安全的PET示踪剂在帕金森病诊断与监测方面具有临床应用潜力。
研究设计与样本
- 研究采用单侧损毁帕金森病模型大鼠进行PET成像,并对死后脑切片进行体外放射自显影。
- 研究纳入假手术组及轻度、中度、重度损毁组大鼠,并比较一名帕金森病患者与一名健康受试者的死后纹状体切片。
- 由大鼠生物分布数据外推估算人体剂量学。
主要发现
- 立体定向注射6-OHDA的大鼠损毁侧纹状体特异性摄取降低。
- 与假手术组相比,轻度、中度、重度损毁组损毁侧与对侧纹状体SUV比值分别下降13%、23%、63%。
- PET显示的帕金森病模型大鼠多巴胺能去神经支配得到行为学评估、免疫染色和单胺浓度检测的支持。
- 微型PET结果与上述测量呈正相关,但与阿扑吗啡诱导的旋转行为试验呈负相关。
- 帕金森病患者死后纹状体切片的[18F]FECNT-d4摄取较健康受试者约低40%。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 人体剂量学由大鼠生物分布数据外推估算。
- 帕金森病患者与健康受试者比较仅基于死后纹状体切片,原文未报告样本量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Parkinson's disease (PD) is a prevalent neurodegenerative disorder worldwide, diagnosed based on classic symptoms like motor dysfunction and cognitive impairments. With the development of various radioactive ligands, positron emission tomography (PET) imaging combined with specific radiolabelling probes has proven to be effective in aiding clinical PD diagnosis. Among these probes, 2β-Carbomethoxy-3β-(4-chlorophenyl)-8-(2-[18F]-fluoroethyl) nortropane ([18F]FECNT) has been utilized as a PET tracer to image dopamine transporter (DAT) integrity in striatal presynaptic dopaminergic terminals. However, the presence of brain-penetrant radioactive metabolites produced by [18F]FECNT may impact the accuracy of PET imaging. In previous research, we developed 2β-Carbomethoxy-3β-(4-chlorophenyl)-8-(2-[18F]-fluoroethyl-1,1,2,2-d4) nortropane ([18F]FECNT-d4), a deuterated derivative with enhanced stability in plasma and the striatum, along with a slower washout rate. In this study, we further investigated the potential of [18F]FECNT-d4 to detect dopaminergic neuron degeneration in Parkinson's disease. This involved PET imaging in unilaterally-lesioned PD model rats and in vitro autoradiography conducted on postmortem brain sections. RESULTS: PET images revealed reduced specific uptake in the ipsilateral striatum of rats stereotactically injected with 6-hydroxydopamine hydrochloride (6-OHDA). Compared to the sham group, the ratio of standardized uptake value (SUV) in the ipsilateral to contralateral striatum decreased by 13%, 23%, and 63% in the mild, moderate, and severe lesioned groups, respectively. Dopaminergic denervation observed in PET imaging was further supported by behavioral assessments, immunostaining, and monoamine concentration tests. Moreover, the microPET results exhibited positive correlations with these measurements, except for the apomorphine-induced rotational behavior test, which showed a negative correlation. Additionally, [18F]FECNT-d4 uptake was approximately 40% lower in the postmortem striatal sections of a PD patient compared to a healthy subject. Furthermore, estimated human dosimetry (effective dose equivalent: 5.06 E-03 mSv/MBq), extrapolated from rat biodistribution data, remained below the current Food and Drug Administration limit for radiation exposure. CONCLUSION: Our findings demonstrate that [18F]FECNT-d4 accurately estimates levels of dopaminergic neuron degeneration in the 6-OHDA-induced PD rat model and effectively distinguishes between PD patients and healthy individuals. This highly sensitive and safe PET probe holds promising potential for clinical application in the diagnosis and monitoring of Parkinson's disease.
引用
- Tang J, Liu C, Liu C, et al. Evaluation of damage discrimination in dopaminergic neurons using dopamine transporter PET tracer [18F]FECNT-d4. EJNMMI Res. 2024. PMID: 39210186. doi:10.1186/s13550-024-01140-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。